All Blogs
Apr 02, 2026
Restore Robotics Secures FDA 510(k) Clearance for Two New da Vinci Xi® Instruments; Medtronic Wins FDA Approval for OmniaSecure™ Defibrillation Lead Enabling Conduction System Pacing; Bebird Introduces EarSight Ultra; BD Introduces AI-Driven Medication Dispensing System in Europe; i-Lumen Scientific Secures FDA IDE Approval to Launch U.S. Enrollment for i-SIGHT2 Dry AMD Trial; Belay Diagnostics Highlights 82% Clinical Impact Rate in CNS Lymphoma Evaluation
Restore Robotics Received FDA 510(k) Clearance for Two Additional da Vinci Xi® Robotic Instruments On 31 March 2026, Restore Robotics announced that it had received an additional 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the remanufacturing of two more da Vinci Xi robotic surgic...
Read More...
Apr 01, 2026
AI Integration in Radiopharmaceuticals: Transforming Precision Diagnostics and Targeted Therapy
Radiopharmaceuticals are a cornerstone of precision medicine, enabling clinicians to visualize disease at the molecular level while simultaneously delivering targeted radionuclide therapy to tumors and other pathological tissues. Their dual diagnostic and therapeutic potential has positioned them as a transformativ...
Read More...
Mar 31, 2026
Tanabe Pharma Shares Encouraging Phase 3 Data for Dersimelagon in Rare Photodermatoses; Biogen’s Litifilimab Demonstrates Significant Skin Disease Reduction in Phase 2 CLE Trial; Merck’s WINREVAIR Shows Promising Phase 2 Results in CpcPH-HFpEF Population; AstraZeneca’s Tozorakimab Meets Primary Endpoints in OBERON and TITANIA Phase III COPD Trials; Amgen’s REPATHA Shows Strong Cardiovascular Risk Reduction in High-Risk Patients
Tanabe Pharma Reports Positive Phase 3 INSPIRE Results for Dersimelagon in EPP and XLP Tanabe Pharma Corporation has announced detailed findings from the Phase 3 INSPIRE trial evaluating investigational oral dersimelagon in patients with erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP). The ...
Read More...
Mar 30, 2026
Denali’s AVLAYAH Win for Hunter Syndrome Marks Turning Point for Rare Disease Innovation
Summary AVLAYAH (tividenofusp alfa‑eknm) has received FDA accelerated approval as the first Hunter syndrome therapy specifically designed to treat neurologic manifestations by crossing the blood–brain barrier. The drug uses Denali’s TransportVehicle platform to fuse the IDS enzyme with a transferrin‑receptor...
Read More...
Mar 27, 2026
GSK’s LYNAVOY Enters PBC Treatment Space, Targeting High-Burden Pruritus Segment
Summary LYNAVOY is an oral IBAT inhibitor approved to treat cholestatic pruritus in adults with PBC, making it the first medicine in the US specifically cleared for this indication. Up to 89% of people with PBC experience cholestatic pruritus, an internal, often unbearable itch that can disrupt sleep, aggrav...
Read More...
Mar 26, 2026
LiviWell Receives FDA Clearance for Livi, Pioneering Post-Intercourse Vaginal Care; Medtronic Advances Spine and Cardiac Care with ViaVerte Partnership and FDA Approval of OmniaSecure Lead; ZEISS Broadens Its Ophthalmic Workflow Portfolio in Canada; Starlight Cardiovascular Reports First-Ever Infant Treated with Lifeline Stent System at Cincinnati Children’s Hospital; Belay Diagnostics Highlights 82% Clinical Impact Rate for Summit™ and Vantage™ in CNS Lymphoma
LiviWell Secured FDA Clearance for Livi, Introducing a New Category in Post-Intercourse Vaginal Care On 24 March 2026, LiviWell announced that the U.S. Food and Drug Administration had granted clearance for Livi, a novel device developed to support vaginal health by absorbing semen and other post-intercour...
Read More...
Mar 25, 2026
Molecular Diagnostics: Bridging the Gap Between Diagnosis and Treatment
Molecular diagnostics is a rapidly advancing field within laboratory medicine that applies molecular biology techniques to detect and quantify specific DNA or RNA sequences. By enabling earlier detection, greater diagnostic accuracy, and more informed clinical decision-making, these technologies have become indispe...
Read More...
Mar 24, 2026
Sanofi’s Venglustat Gains US Breakthrough Therapy Nod, Boosting Hope for Type 3 Gaucher Disease; Rhythm Pharmaceuticals Expands IMCIVREE Label with FDA Approval in Hypothalamic Obesity; FDA Approves LYNAVOY for Cholestatic Pruritus in PBC Patients; FDA Greenlights J&J/Protagonist’s ICOTYDE, Redefining First-Line Systemic Therapy for Plaque Psoriasis; Novartis Strengthens its Breast Cancer Portfolio Through Acquisition of a Pan-mutant PI3Kα Inhibitor
Sanofi Wins US Breakthrough Therapy Tag for Venglustat in Type 3 Gaucher Disease The US Food and Drug Administration (FDA) has awarded Breakthrough Therapy designation to venglustat, an investigational oral glucosylceramide synthase inhibitor (GCSi), for treating neurological symptoms associated with type 3 Gauc...
Read More...
Mar 23, 2026
J&J and Protagonist’s ICOTYDE Ushers in First-in-Class Oral IL-23 Therapy
Summary Johnson & Johnson and Protagonist Therapeutics received U.S. FDA approval for ICOTYDE (icotrokinra), the first targeted oral IL-23 receptor peptide therapy for moderate-to-severe plaque psoriasis in adults and adolescents (12+ years, ≥40 kg). Once-daily 200 mg oral tablet blocks IL-23 signaling w...
Read More...
Mar 20, 2026
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Summary Radioligand therapy is quickly establishing itself as a transformative force in oncology, with demand accelerating so rapidly that manufacturers are under pressure to scale up production. Among the leaders, Novartis is advancing its late-stage candidate 225Ac-PSMA-617, while a growing competitive lan...
Read More...